Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as the Company's independent auditor of its own initiative, and that MNP LLP ("MNP") has been engaged as the Company's new independent auditor. Regardless of the change, the audit of the Company's financial statements for the year ended August 31, 2025, is on track to be completed by MNP by the end of November 2025.
The reports of Davidson for all financial years for which it acted as auditor (i.e. for the years ended August 31, 2024, August 31, 2023, August 31, 2022, August 31, 2021 and August 31, 2020) did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. There were no reportable events (as defined in National Instrument 51-102) in connection with the service of Davidson as auditor of the Company.
The change of independent auditor for the Company has been considered and approved by its Audit Committee and its Board of Directors.
The Company continues to be in the process of lifting the foregoing cease trade order and relisting on another reputable exchange.
For more information:
Investor Contact
Craig MacPhail
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | C$0.05 |
| Daily Volume: | 0 |
| Market Cap: | C$16.030M |
September 03, 2025 August 20, 2025 August 08, 2025 March 20, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load